Detect biomarkers associated with Nonalcoholic Fatty Liver Disease (NAFLD)
Using the SomaScan® Assay to identify new biomarkers in liver disease
Abstract
In this 1-hour discussion, learn how the SomaScan Assay can be used to detect biomarkers associated with NAFLD—specifically, the identification of circulating proteins associated with fibrosis in NAFLD using a custom 5k-plex SomaScan Assay. Also discussed is the importance of identifying non-invasive biomarkers that improve clinical decision-making and drug development for NAFLD, and the strategies for multiplexed validation of candidate biomarkers discovered using the SomaScan Assay.
Kathleen Corey, MD, MPH, MMSc
Director of the Massachusetts General Hospital NAFLD program and an Assistant Professor of Medicine at Harvard Medical School
Rebecca Pitts
Principal scientist at the Novartis Institutes for BioMedical Research in Cambridge, Massachusetts
Advancing biomarkers for Nonalcoholic Fatty Liver Disease using proteomics
A webinar presented by Kathleen Corey, MD, MPH, MMSc, and Rebecca Pitts
More webinars
WebinarHuman proteomics: from the operating room to the lab and back
Optimizing platforms for surgical specimen collection and deep human phenotyping was used to enhance protein biomarker identification using proteomic tools. A series of studies using human eye fluids has helped to diagnose inflammatory retinal disease, select personalized therapies, stage cancer, and point to new therapeutic strategies. These approaches can be broadly applied to human surgical disease.
Webinar10 things I hate about proteomics
Dr. Williams explains in a fun - but serious - way how proteomics is revolutionizing drug discovery research and precision medicine worldwide today. He also couldn't resist telling the story about what happens when two proteins walk into a bar.